| Entry |
|
|---|
| Name |
Cytarabine (JP18/USP/INN);
ARA-C;
Depocyt (TN) |
|---|
| Product |
|
|---|
| Generic |
CYTARABINE (Fresenius Kabi USA), CYTARABINE (Gland Pharma Limited), CYTARABINE (Gland Pharma Limited), CYTARABINE (Hospira), CYTARABINE (Hospira), CYTARABINE (Hospira), CYTARABINE (Hospira), CYTARABINE (Meitheal Pharmaceuticals), CYTARABINE (Meitheal Pharmaceuticals), CYTARABINE (Meitheal Pharmaceuticals), CYTARABINE (Meitheal Pharmaceuticals), CYTARABINE (Sagent Pharmaceuticals), CYTARABINE (Sagent Pharmaceuticals) |
|---|
| Formula |
C9H13N3O5
|
|---|
| Exact mass |
243.0855
|
|---|
| Mol weight |
243.2166
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
|
|---|
| Remark |
| Therapeutic category: | 4224 |
| Product (DG00686): | D00168<JP/US> D03046<JP> |
| Product (mixture): | D11390<US> |
|
|---|
| Efficacy |
Antineoplastic, Antimetabolite, DNA polymerase inhibitor |
|---|
| Disease |
Lymphomatous meningitis [DS: H01668] Acute myeloid leukemia [DS: H00003] Chronic myelocytic leukemia [DS: H00004] |
|---|
| Comment |
Active metabolite: Cytarabine-5;-triphosphate (ara-CTP)
|
|---|
| Target |
DNA polymerase |
|---|
| Interaction |
|
|---|
| Structure map |
| map07041 | Antineoplastics - antimetabolic agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01B ANTIMETABOLITES
L01BC Pyrimidine analogues
L01BC01 Cytarabine
D00168 Cytarabine (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antimetabolites
Cytarabine
D00168 Cytarabine (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
422 Antimetabolites
4224 Cytosines
D00168 Cytarabine (JP18/USP/INN)
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG00686 Cytarabine
D00168 Cytarabine
Drug classes [BR:br08332]
Antineoplastic
DG02018 Antimetabolite
D00168 Cytarabine
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00168 Cytarabine
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00168
Prodrugs [br08324.html]
D00168
Drug groups [BR:br08330]
Antineoplastic
DG02018 Antimetabolite
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
DG00686 Cytarabine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 17
1 C1y C 22.3986 -17.4645
2 N4y N 23.7916 -16.8812
3 O2x O 21.2637 -16.6396
4 C1y C 21.9658 -18.7927
5 C8y C 25.0030 -17.5661
6 C8x C 23.7682 -15.4827
7 C1y C 20.1286 -17.4645
8 C1y C 20.5616 -18.7927
9 O1a O 22.7848 -19.9278
10 N5x N 26.2080 -16.8485
11 O5x O 25.0208 -18.9659
12 C8x C 24.9731 -14.7651
13 C1b C 18.7947 -17.0317
14 O1a O 19.7425 -19.9278
15 C8y C 26.1901 -15.4486
16 O1a O 17.7591 -17.9735
17 N1a N 27.3966 -14.7369
BOND 18
1 1 2 1 #Up
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 1
7 4 8 1
8 4 9 1 #Up
9 5 10 1
10 5 11 2
11 6 12 2
12 7 13 1 #Up
13 8 14 1 #Down
14 10 15 2
15 13 16 1
16 15 17 1
17 7 8 1
18 12 15 1
|
|---|
